- Home
- CLDI vs CANF Comparison
CLDI vs CANF Comparison
Compare CLDI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- CANF
- Stock Information
- Founded
- CLDI 2014
- CANF 1994
- Country
- CLDI United States
- CANF Israel
- Employees
- CLDI N/A
- CANF N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- CANF Health Care
- Exchange
- CLDI Nasdaq
- CANF Nasdaq
- Market Cap
- CLDI 15.7M
- CANF 14.8M
- IPO Year
- CLDI N/A
- CANF N/A
- Fundamental
- Price
- CLDI $0.40
- CANF $1.04
- Analyst Decision
- CLDI Strong Buy
- CANF Strong Buy
- Analyst Count
- CLDI 2
- CANF 2
- Target Price
- CLDI $15.00
- CANF $14.00
- AVG Volume (30 Days)
- CLDI 202.0K
- CANF 172.6K
- Earning Date
- CLDI 05-20-2025
- CANF 05-27-2025
- Dividend Yield
- CLDI N/A
- CANF N/A
- EPS Growth
- CLDI N/A
- CANF N/A
- EPS
- CLDI N/A
- CANF N/A
- Revenue
- CLDI N/A
- CANF $674,000.00
- Revenue This Year
- CLDI N/A
- CANF $461.72
- Revenue Next Year
- CLDI N/A
- CANF N/A
- P/E Ratio
- CLDI N/A
- CANF N/A
- Revenue Growth
- CLDI N/A
- CANF N/A
- 52 Week Low
- CLDI $0.35
- CANF $1.02
- 52 Week High
- CLDI $4.90
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- CLDI 36.62
- CANF 37.30
- Support Level
- CLDI $0.40
- CANF $0.98
- Resistance Level
- CLDI $0.46
- CANF $1.14
- Average True Range (ATR)
- CLDI 0.04
- CANF 0.06
- MACD
- CLDI 0.00
- CANF 0.01
- Stochastic Oscillator
- CLDI 9.73
- CANF 32.59
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).